Luyan Pharmaceutical announced that the cumulative deviation value of the company's stock trading price increase exceeded 20% in two consecutive trading days, which was an abnormal fluctuation in stock trading. It has been verified that there are no corrections or additions to the information disclosed earlier by the company. Recently, the company's business situation is normal, there have been no major changes in the internal and external business environment, and the company, controlling shareholders and actual controllers have no important matters relating to the company that should be disclosed but not disclosed, or that are in the planning stage. During the period of abnormal stock fluctuations, the controlling shareholder or actual controller did not trade the company's shares.

Luyan Pharmaceutical announced that the cumulative deviation value of the company's stock trading price increase exceeded 20% in two consecutive trading days, which was an abnormal fluctuation in stock trading. It has been verified that there are no corrections or additions to the information disclosed earlier by the company. Recently, the company's business situation is normal, there have been no major changes in the internal and external business environment, and the company, controlling shareholders and actual controllers have no important matters relating to the company that should be disclosed but not disclosed, or that are in the planning stage. During the period of abnormal stock fluctuations, the controlling shareholder or actual controller did not trade the company's shares.